Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 13/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.39 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086467 | 1.00 | PARP1 (0.45) | PARP1PARP2P2RX7TIPARPPARP8 | |
| SCHEMBL3085173 | 0.92 | PARP1 (0.42) | PARP1PARP2TIPARPPARP8PARP3 | |
| SCHEMBL3082595 | 0.87 | PARP1 (0.51) | PARP1PARP2 | |
| SCHEMBL3081795 | 0.86 | PARP1 (0.39) | PARP1PARP2TIPARPPARP8PARP3 | |
| SCHEMBL3063144 | 0.86 | PARP1 (0.39) | PARP1PARP2TIPARPPARP8PARP3 | |
| SCHEMBL3075557 | 0.85 | PARP1 (0.38) | PARP1PARP2 | |
| SCHEMBL3069229 | 0.85 | PARP1 (0.46) | PARP1PARP2 | |
| SCHEMBL3075534 | 0.84 | PARP1 (0.40) | PARP1PARP2 | |
| SCHEMBL3068979 | 0.84 | PARP1 (0.44) | PARP1PARP2 | |
| SCHEMBL3080936 | 0.84 | PARP1 (0.51) | PARP1PARP2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220073-B1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA SRL (IT) | 2014-09-03 | — | — | EP | claimed |
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | claimed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | claimed |
| EP-2220073-B1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA SRL (IT) | 2014-09-03 | — | — | EP | disclosed |
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | disclosed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885P2RX7 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.